Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

PROFIT WARNING

This announcement is made by Sisram Medical Ltd (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 and the assessment of the latest information currently available to the Board, the Group is expected to record (i) revenue of no less than US$171.0 million for the six months ended June 30, 2026, as compared to that of US$165.5 million for the corresponding period in 2025; and (ii) a loss attributable to owners of the Company in the range of approximately US$0.9 million to US$1.4 million for the six months ended June 30, 2026, as compared to a profit attributable to owners of the Company of US$6.4 million for the corresponding period in 2025.

Based on the information currently available, the Board is of the view that such expected record of a loss attributable to owners of the Company for the six months ended June 30, 2026 is mainly attributable to: (i) the lower sales in North America amid the persistent challenging market conditions; and (ii) continued investment in the Company's injectable business in Mainland China. Despite the aforementioned operational challenges, the Group's revenue recorded growth throughout the first half of 2026, driven by (i) robust growth across APAC, Europe, and the Middle East and Africa; and (ii) the increasing contributions from the Injectables segment.

The Group is closely monitoring market developments and is taking targeted actions to strengthen execution and adapt its operations to current market conditions. These actions include sharpening commercial execution and improving cost alignment in North America, while accelerating the expansion of DAXXIFY and local manufacturing capabilities in China. At the same time, the Group will continue to invest selectively in strategic initiatives, product innovation and ecosystem integration, and pursue opportunities that strengthen its product pipeline and technological capabilities, with a view to supporting sustainable long-term growth and value creation.

The information contained herein is only based on a preliminary assessment of the information currently available to the Board as at the date of this announcement and which has not been confirmed and reviewed by the audit committee of the Board and has not been audited and reviewed by the Company's auditors. As at the date of this announcement, the Group is still in the course of preparing and finalizing its interim results for the six months ended June 30, 2026 and such interim results may be subject to further adjustments and may be different from the information contained in this announcement. Shareholders and potential investors of the Company are advised to carefully read the interim results announcement of the Company for the six months ended 30 June 2026, which will be published by the end of August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, August 3, 2026

As at the date of this announcement, the Board comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purposes only*